(New York, NY) – March 24th, 2014 – AiCure, an artificial intelligence company providing advanced facial recognition solutions to monitor medication adherence, was invited to present during the poster session at World TB Day Symposium: Countdown to 2015 in New York City. AiCure showcased the technology and its applicability in accurately monitoring patients being treated for TB.
Traditionally, treatment for active TB has required patients to be directly observed while taking their medication. While effective in achieving high adherence rates, the high cost and resource-intensive nature of DOT has strained health budgets and led health departments to look for alternatives. Recent studies have also shown that even for shorter treatment courses such as the newly-approved three-month regimen for latent TB, a major barrier to adoption by patients has been the requirement for DOT. AiViewTM, which is available in multiple languages as an app on smartphones and tablets, visually and automatically confirms that the right patient is taking the right medication at the right time. Unlike video dosing which is already being used across several states, AiViewTM does not require human review, thus lowering the cost of implementation even further.